Scancell (LON:SCLP) Issues Quarterly Earnings Results

Scancell (LON:SCLP) announced its quarterly earnings data on Thursday. The company reported GBX (0.55) EPS for the quarter, Digital Look Earnings reports.

Scancell Trading Up 3.8%

LON:SCLP opened at GBX 13.49 on Friday. The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The company’s 50-day simple moving average is GBX 10.77 and its 200 day simple moving average is GBX 10.21. Scancell has a one year low of GBX 7.26 and a one year high of GBX 14. The firm has a market capitalization of £140.00 million, a P/E ratio of -10.71 and a beta of 0.35.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.